Moleculin Completes Part A of Phase 2/3 MIRACLE Trial for Annamycin
Moleculin Biotech reported Q3 2026 financial results and announced completion of patient treatment in the MIRACLE trial, targeting a first-quarter 2027 data readout for the AML treatment Annamycin.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed